SK Hynix Shares Drop After Strong Nasdaq Debut Despite $26 Billion ADR Listing 
Morgan Stanley Says China’s Reusable Rocket Progress Poses Long-Term Challenge to SpaceX 
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO 
TSMC Q2 Revenue Surges 36% as AI Chip Demand Powers Growth Ahead of Earnings 
Mastercard Explores Sale of Majority Stake in UK Payments Firm Vocalink: Report 
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates 
Nvidia Tightens AI Chip Sales in Asia With Stricter Customer Approval Process 
Stellantis Q2 Vehicle Shipments Rise 10% as North America Drives Growth 
Deutsche Bank Fined A$2 Million by ASIC Over OTC Derivatives Reporting Errors 
SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand 
Muji Owner Ryohin Keikaku Stock Soars After Raising Full-Year Earnings Forecast 
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 
Yaskawa Electric Shares Slide as Weak Profit Overshadows Strong AI Demand 
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth 
Genesis Minerals to Acquire Vault in A$5.6 Billion Deal After Regis Withdraws 
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia 
WASHINGTON, DC, Jan. 6, 2016 (GLOBE NEWSWIRE) -- The Association of Clinical Research Organizations (ACRO) is pleased to announce that its Board of Directors has elected David Simmons, Chairman and CEO of PPD, as its 2016 Chairman, and John Hubbard, President and CEO of Bioclinica, as Vice Chairman.
"ACRO plays a vital role in promoting the interests of the CRO industry globally," said Simmons. "Not only does ACRO represent the industry on legislative and regulatory matters but, increasingly, the association helps build relationships with the sponsor, research site, investigator and patient communities. I look forward to leading the organization in 2016 as we pursue a focused and productive agenda."
|
|||||
Simmons added that, in addition to its legislative and regulatory priorities, ACRO is exploring further ways to benefit the industry in areas such as patient recruitment, workforce development and clinical trial efficiency.
"ACRO successfully advanced CRO industry interests in 2015 by influencing health and tax policy in the United States and navigating the implementation of the Clinical Trial Regulation in the European Union," said ACRO Executive Director Doug Peddicord, Ph.D. "We will build on our successes this year and continue to promote our industry through our robust communications and advocacy programs."
ACRO also elected as officers: Judd Hartman, General Counsel of PPD, as Treasurer; and Maria Kraus, Executive Vice President of Corporate Development and Strategy at Bioclinica, as Secretary.
About ACRO
The Association of Clinical Research Organizations (ACRO) represents companies that provide a variety of specialized services that support the development of new pharmaceuticals, biologics, and medical devices. The Association provides an active voice for the CRO industry globally. Through its member companies, ACRO helps improve the quality, efficiency and safety of biomedical research. ACRO member companies employ more than 110,000 professionals worldwide and conduct research in 142 countries. For more information, please visit www.acrohealth.org. Twitter @acrohealth. YouTube @ACROHealthChannel. Facebook. RebelMouse.
A photo accompanying this release is available at:
http://www.globenewswire.com/newsroom/prs/?pkgid=38345
CONTACT: John Lewis
[email protected]
202-464-9340
